Selected article for: "lmwh weight heparin and low molecular lmwh weight heparin study"

Author: Fogarty, Helen; Townsend, Liam; Ni Cheallaigh, Cliona; Bergin, Colm; Martin‐Loeches, Ignacio; Browne, Paul; Bacon, Christopher L.; Gaule, Richard; Gillett, Alexander; Byrne, Mary; Ryan, Kevin; O'Connell, Niamh; O'Sullivan, Jamie M.; Conlon, Niall; O'Donnell, James S.
Title: More on COVID‐19 coagulopathy in Caucasian patients
  • Cord-id: 4f25h9l4
  • Document date: 2020_5_25
  • ID: 4f25h9l4
    Snippet: We are grateful for the comments of Marrietta et al, [1] and welcome the opportunity to provide further details on the coagulopathy observed in our patients with COVID-19 infection [2]. The weight-adjusted low molecular weight heparin (LMWH) thromboprophylaxis used in the study is that routinely used for hospital in-patients in our institution, consistent with national recommendations [3,4] With respect to the cohort of patients with COVID-19 enrolled in our study, it is important to highlight t
    Document: We are grateful for the comments of Marrietta et al, [1] and welcome the opportunity to provide further details on the coagulopathy observed in our patients with COVID-19 infection [2]. The weight-adjusted low molecular weight heparin (LMWH) thromboprophylaxis used in the study is that routinely used for hospital in-patients in our institution, consistent with national recommendations [3,4] With respect to the cohort of patients with COVID-19 enrolled in our study, it is important to highlight that 74% of patients received enoxaparin 40mg (4000 IU) subcutaneously once daily.

    Search related documents:
    Co phrase search for related documents
    • lmwh lowmolecular weight heparin and lowmolecular weight: 1
    • lmwh lowmolecular weight heparin and lowmolecular weight heparin: 1